

Rec'd PGT/PTO 15 FEB 2005

003/005

FEB-15-2005 TUE 05:51 PM astra zeneca r&d boston

FAX NO. 17818394121

P. 02

RECEIVED

CENTRAL FAX CENTER
107509633
FEB 16 2005

PTO/SB/22 (08-04)

Approved for use through 11/30/2008, OMB 0851-0035
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	10/509633
	Filing Date	September 29, 2004
	First Named Inventor	Jean-Claude Arnould
	Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	100487-1P US

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint Lucy Clare Padgett (Limited Recognition Under 37 CFR §11.8(b)), Christine Catherine McCormack (Limited Recognition Under 37 CFR §10.8(b)) and all practitioners associated with the Customer Number:

44992

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with Customer Number:

44992

OR

☐ Firm or Individual Name AstraZeneca Pharmaceuticals LP


Address	Global Intellectual Property 35 Gatehouse Drive				
City	Waltham				
Country	USA	State	MA	Zip	02451
Telephone	(781) 839-4000			Fax	(781) 839-4500

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/98)

SIGNATURE of Applicant or Assignee of Record

Signature			
Name	KEVIN BILE		
Date	9 February 2005	Telephone	011 44 1625 512461

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of 1 forms are submitted.

BEST AVAILABLE COPY

FEB-15-2005 TUE 05:52 PM astra zeneca r&d boston

FAX NO. 17818394121

P. 01/02

10/509633

PTO/SB/96 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Jean-Claude Amould

Application No.:

10/509633Filed: September 29, 2004Entitled: INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITYAstraZeneca ABCorporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %
- In the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.
(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

[Signature]
SignatureKEVIN BILL
Printed or Typed Name

Authorized Signer for Assignee

Title:

Authorized Officer
Patent Director, CV9 February 2005
Date01144 1625 512461
Telephone Number

Rec'd PCT/PTO 15 FEB 2005
 10/509633

ATTORNEY DOCKET NO.: 056291-
 AstraZeneca Ref: 100467-1P US

ASSIGNMENT

For good and valuable consideration, receipt of which is hereby acknowledged, ASSIGNOR (S),

ARNOULD, Jean, Claude

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE AstraZeneca AB, a company created and existing under the laws of Sweden, having its Head Office at SE-151 85 Sodertalje, Sweden, and the successors assign and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY

And which is found in:

- (a) ___ U.S. patent application executed on even date herewith;
- (b) ___ U.S. patent application executed on _____;
- (c) ___ U.S. application serial no. Filed on _____;
- (d) X International application no. PCT/GB03/01405 filed on 31 March 2003 (31.03.2003).

And any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to Letters Patent or any reissue or reexamination thereof;

ASSIGNOR (S) hereby covenant(s) that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR (S) further covenant(s) that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

IN TESTIMONY WHEREOF, I/WE have hereunto set our hand(s).

Full Name of Sole or First Assignor	Assignor's Signature	Date
ARNOULD, Jean, Claude	Jean Claude Arnould.	10 th August 2006
Address	Citizenship:	
AstraZeneca R & D Reims, Z.I. La Pompelle, BP 1050, F-51689, Reims Cedex 2, France	France	
Names of additional inventors attached <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		

BEST AVAILABLE COPY